Yesterday, Dec. 22, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $102.00 to $44,180,000.00.

Highlighted Stocks Traded by Insiders:

St Jude Medical (STJ) - FREE Research Report

Heinmiller John C, who is Executive Vice President at St Jude Medical, sold 8,009 shares at $61.16 on Dec. 22, 2015. Following this transaction, the Executive Vice President owned 237,211 shares meaning that the stake was reduced by 3.27% with the 8,009-share transaction.

Zurbay Donald, who is VP Finance and CFO at St Jude Medical, sold 3,106 shares at $60.96 on Dec. 22, 2015. Following this transaction, the VP Finance and CFO owned 19,284 shares meaning that the stake was reduced by 13.87% with the 3,106-share transaction.

Dallager Jeff, who is VP and Corporate Controller at St Jude Medical, sold 501 shares at $60.94 on Dec. 22, 2015. Following this transaction, the VP and Corporate Controller owned 6,081 shares meaning that the stake was reduced by 7.61% with the 501-share transaction.

The shares most recently traded at $61.48, up $0.54, or 0.88% since the insider transaction. Historical insider transactions for St Jude Medical go as follows:

  • 4-Week # shares sold: 1,596
  • 12-Week # shares sold: 1,596
  • 24-Week # shares sold: 2,455

The average volume for St Jude Medical has been 1.9 million shares per day over the past 30 days. St Jude Medical has a market cap of $17.2 billion and is part of the health care sector and health services industry. Shares are down 5.84% year-to-date as of the close of trading on Tuesday.

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. The stock currently has a dividend yield of 1.9%. The company has a P/E ratio of 17.3. Currently, there are 13 analysts who rate St Jude Medical a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STJ - FREE

TheStreet Quant Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full St Jude Medical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BreitBurn Energy Partners (BBEP) - FREE Research Report

Wolf Donald D, who is Director at BreitBurn Energy Partners, bought 5,913 shares at $0.56 on Dec. 22, 2015. Following this transaction, the Director owned 11,826 shares meaning that the stake was boosted by 100% with the 5,913-share transaction.

The shares most recently traded at $0.69, up $0.13, or 18.59% since the insider transaction. Historical insider transactions for BreitBurn Energy Partners go as follows:

  • 4-Week # shares bought: 25,000
  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 25,000
  • 12-Week # shares sold: 15,000
  • 24-Week # shares bought: 25,000
  • 24-Week # shares sold: 15,000

The average volume for BreitBurn Energy Partners has been 2.3 million shares per day over the past 30 days. BreitBurn Energy Partners has a market cap of $108.0 million and is part of the basic materials sector and energy industry. Shares are down 91.42% year-to-date as of the close of trading on Tuesday.

Breitburn Energy Partners LP, an independent oil and gas partnership, acquires, exploits, and develops oil, natural gas liquids (NGLs), and natural gas properties in the United States. The stock currently has a dividend yield of 39.68%. Currently, there is 1 analyst who rates BreitBurn Energy Partners a buy, 1 analyst rates it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BBEP - FREE

TheStreet Quant Ratings rates BreitBurn Energy Partners as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full BreitBurn Energy Partners Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Century Bancorp (CNBKA) - FREE Research Report

Filler James J, who is 10% Owner at Century Bancorp, bought 5 shares at $43.90 on Dec. 22, 2015. Following this transaction, the 10% Owner owned 486,671 shares meaning that the stake was boosted by 0% with the 5-share transaction.

Evangelista Paul A, who is Executive Vice President at Century Bancorp, bought 4 shares at $44.54 on Dec. 22, 2015. Following this transaction, the Executive Vice President owned 5,624 shares meaning that the stake was boosted by 0.08% with the 4-share transaction.

The shares most recently traded at $44.49, down $0.05, or 0.11% since the insider transaction. Historical insider transactions for Century Bancorp go as follows:

  • 4-Week # shares bought: 7,142
  • 12-Week # shares bought: 20,881
  • 24-Week # shares bought: 503,346

The average volume for Century Bancorp has been 3,200 shares per day over the past 30 days. Century Bancorp has a market cap of $156.7 million and is part of the financial sector and banking industry. Shares are up 8.05% year-to-date as of the close of trading on Monday.

Century Bancorp, Inc. operates as a bank holding company for Century Bank and Trust Company that provides banking products and services in Massachusetts. The stock currently has a dividend yield of 1.1%. The company has a P/E ratio of 10.7.

Exclusive Offer: Get the latest Stock Analysis on CNBKA - FREE

TheStreet Quant Ratings rates Century Bancorp as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Century Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.